Recombinant Dog Mast/stem cell growth factor receptor Kit (KIT), partial

1. the pan deubiquitinating enzyme inhibitor PR619 prevented imatinib induction of KIT overexpression, suggesting that the imatinib-induced decrease in KIT ubiquitination could be mediated by upregulation and/or activation of deubiquitinating enzyme(s). It may be possible that a similar mechanism of KIT overexpression underlies the acquisition of imatinib resistance in some human tumors that are driven by KIT mutation. PMID: 28765927
2. Tumors with KIT mutations showed genome-wide aberrant copy number profiles, with frequent CNAs (DNA copy number aberrations) involving genes in the p53 and RB pathways, whereas CNAs were very limited in tumors with wild-type KIT PMID: 28058543
3. KTN0158 inhibits KIT phosphorylation, demonstrates an acceptable safety profile in dogs, and provides objective responses in canine MCT patients with and without activating KIT mutations, supporting future clinical evaluation of KTN0158 in people. PMID: 27815356
4. the high incidence of GNSK-deletion c-kit in canine HSAs implicates KIT isoforms as possibly participating in the tumorigenesis of canine hemangiosarcomas. PMID: 27422008
5. data indicate that c-KIT exon 11 mutations occur frequently in canine gastrointestinal stromal tumours PMID: 26631948
6. These findings indicate that canine gastrointestinal stromal, and possibly mast cell tumors,may be responsive to molecular-targeted therapy. PMID: 26074249
7. Ki67(-)/KIT(+) animals had a longer survival time than Ki67(+)/KIT(+) animals (p=0.03). PMID: 26412531
8. This is the first report demonstrating the tumorigenic potential of a mutation in the extracellular domain of KIT. PMID: 25965812
9. The relationship between KIT gene expression and tumor recurrence and mortality in dogs with cutaneous mast cell tumors was investigated via RT-PCR and immunohistochemistry. PMID: 23294979
10. Substantial genetic heterogeneity across SLC6A3 demonstrated within a single breed suggests that effects of SLC6A3 on behavior may be complex and wide ranging. PMID: 23659249
11. This study analyzed c-kit mRNA and protein expression and mutations in B-cell and T-cell canine lymphomas using an integrated analytic approach. PMID: 23791075
12. These findings suggest that a subset of canine malignant melanomas harbors a KIT exon 11 mutation. PMID: 23069279
13. These findings demonstrate that the Kiupel grading system is a useful prognostic tool for canine cutaneous mast cell tumors in predicting overall and progression free survival (PFS); occurrence of ITD-Exon11 appeared to be a useful predictor of PFS. PMID: 23384436
14. Tandem duplication of KIT exon 11 influences the proteome of canine mast cell tumours PMID: 22935087
15. Mutations on c-KIT exons 8-11 and 17 were investigated by cDNA sequencing. Higher amounts of c-KIT mRNA were found in acute leukemia compared to chronic lymphocytic leukemia, and the latter showed a lower pattern of gene expression. PMID: 23375718
16. In the gliomas reported in this study, none expressed COX2; none were immunoreactive for c-kit, although all three high-grade tumours had intramural vascular expression. PMID: 22235799
17. Transcriptome analysis of the mast cell line C2 treated for up to 72 h with masitinib identified significant changes in the expression levels of approximately 3500 genes or 16% of the canine genome. PMID: 22747577
18. In canine cutaneous melanocytic tumors c-kit-labeling extension pattern was similar to that usually observed in human tumors. PMID: 22407004
19. The inhibitory effect of four tyrosine kinase inhibitors on proliferation and phosphorylation of c-Kit receptor as well as the expression and function of ABCB1 were investigated in tumor cell lines. PMID: 21480930
20. Histopathological and immunohistological analysis of PLAP, KIT, DAZ and DMRT1 expression revealed that canine seminomas closely resemble human spermatocytic seminomas. PMID: 21615421
21. 20 of 39 cases of malignant oral melanomas were positive for KIT protein, with no significant difference between KIT expression and overall survival. PCR amplification and sequencing of KIT exon 11 in 17 samples did not detect any mutations. PMID: 21848624
22. The utility of c-KIT mutations as prognostic markers for mast cell tumors is reported. PMID: 21160022
23. Canine and human gastrointestinal stromal tumors display similar mutations in c-KIT exon 11 PMID: 20950418
24. In human MC, the KIT D816V mutant introduces resistance, and in canine mastocytomas, an exon 11 polymorphism may be indicative of resistance against INNO-406. PMID: 20685234
25. No c-kit mutations or polymorphisms were identified in exons 16-20 (the phosphotransferase portion of c-KIT's kinase domain) of any mast cell tumors. Such mutations do not play a big role in progression or the aberrant location of KIT in canine MCTs. PMID: 16579858
26. Canine mast cell tumors are an excellent model for characterizing the role of c-KIT in neoplastic diseases and is a potential target for novel therapeutic agents in clinical trials. PMID: 16611403
27. The results of a study evaluating role for c-KIT in the progression of canine mast cell tumors is reported. PMID: 17491070
28. Report that more aggressive biologic behavior of canine mast cell tumors is associated with increased c-kit expression, suggesting a role for c-kit, as a useful marker, in diagnostic pathology and in tumor progression. PMID: 18608529
29. This study shows that activating mutations in not only exon 11 but also exons 8 and 9 are common in canine mast cell tumors. PMID: 18644978
30. RAS, FLT3, and C-KIT mutations, analogous to those found in human leukemia, occur commonly in acute canine leukemia. PMID: 18977066

Show More

Hide All

KEGG: cfa:403811

STRING: 9615.ENSCAFP00000039467

UniGene: Cfa.184